Member Info for TRENCH123

Thanks KH

Will be soon

Definitely not low. Growing revenues, lowering overheads. Good outlook for those invested IMHO

The Doc will probably be after a few more at this price

I think it always fascinating when apparently disinterested people with ulterior motives appear out of the woodwork. Mind games !!

You need to reflect net trade receivables, otherwise the figure is rather meaningless.

Trout, the cash will sort itself out, plenty of good positive vibes from this report - the strongest I have seen for a long time here.

Trout, more than that. At 31st December, 2025 Cash (£257k) + Trade Debtors (£288k) less Trade Payables (144k) = £401k . Cash burn (based on net movement in current assets) in six months to 31 December, 2025 and excluding (say) £50k in exceptional items = £45k/month. This is before anticipated significant reductions in overheads in H2 due to greater use of in-house personnel rather than external contractors. So looking OK

'I have been back in the market at 0.50p area #PYC just as I did with my previous buys including #KEN at 0.30s '

Doc mentioning today on Twitter that he has added more

Avocet, you are posting on the wrong company

Definitely good news. New client in expanding Asian market

You are the guys that sound desperate to me. Calm down

Nice to see Avocet happy with the decent-sized buy

Extract from PYC post yesterday :

'Using the Physiomics Virtual Tumour™, we combine biological and pharmacological data into mechanistic models that simulate how a cancer will respond to a given treatment regimen, often before it reaches the clinic. In practice, this insight helps our partners optimise dosing and scheduling, de-risk combination therapy strategies, and design more targeted clinical trials – all grounded in biological, not just empirical, evidence.

As we can develop these models early in development and update as clinical data is generated, we can offer our clients a clear, model-based rationale for dosing decisions. With the FDA's Project Optimus shifting focus toward the Optimal Biological Dose rather than Maximum Tolerated Dose, that's no small thing'

VT predictive model proven to work successfully over many years and continually being upgraded. Highly undervalued asset IMHO

PS has done a good job in difficult market conditions, but remember JM was the architect of most of the current projects (Biometrics ; partnerships with Beyond Blood, DosemeRx, etc.) which are now coming to fruition. Hence, there is ample management continuity here anyway

Most people take options rather than buying outright themselves. Jesse probably has a mortgage, a young wife and family to support, etc.

Sorry but that tale about PS sounds like a load of old codswallop (or maybe troutswallop !1)

Cheerful Charlie Chester !!

Yes, not much in the way of trades

Avocet, no one interested in selling either. Everyone waiting for news